Preventing Cardiovascular Death with Colchicine Therapy in Post-Myocardial Infarction Patients
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on March 14th, 2025
|
Atherosclerosis and cardiovascular events are linked to a persistent state of increased inflammation. Prior studies have shown that reducing inflammation with canakinumab—an interleukin-1 beta inhibitor—can lower the risk of ischemic events, though this treatment notably raises the risk of infections. Colchicine, which also has anti-inflammatory properties, is being investigated for its potential to prevent cardiovascular incidents, as part of a study sponsored by the Canadian Institutes of Health Research.
The multinational clinical study enrolled 7,062 participants with a mean age of 60, all of whom had previously experienced a myocardial infarction—95% of these patients had elevated ST segments. Nearly all participants (96.3%) underwent percutaneous coronary intervention with the insertion of drug-eluting stents. They were randomly assigned to receive either a daily dose of 0.5 mg colchicine or a placebo. Colchicine’s anti-inflammatory effect is achieved by disrupting inflammasome complexes necessary for interleukin-1 beta production. After a median follow-up of three years, researchers observed that colchicine did not reduce the risk of cardiovascular deaths, including those from stroke or myocardial infarction, a finding consistent with previous studies. Notably, while no increased risk of pneumonia or other serious infections was detected, colchicine use was associated with a higher incidence of diarrhea.
The multinational clinical study enrolled 7,062 participants with a mean age of 60, all of whom had previously experienced a myocardial infarction—95% of these patients had elevated ST segments. Nearly all participants (96.3%) underwent percutaneous coronary intervention with the insertion of drug-eluting stents. They were randomly assigned to receive either a daily dose of 0.5 mg colchicine or a placebo. Colchicine’s anti-inflammatory effect is achieved by disrupting inflammasome complexes necessary for interleukin-1 beta production. After a median follow-up of three years, researchers observed that colchicine did not reduce the risk of cardiovascular deaths, including those from stroke or myocardial infarction, a finding consistent with previous studies. Notably, while no increased risk of pneumonia or other serious infections was detected, colchicine use was associated with a higher incidence of diarrhea.